AzTrials
AzTrials

Intracranial Atherosclerosis ICASCASSISS-DPRNCT07309705

Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis

An observational study of Intracranial Atherosclerosis ICAS and Hemodynamic, run by Xuanwu Hospital, Beijing at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The goal of this observational study is to learn whether a digital angiography derived fractional flow reserve (DPR) measurement can improve the prediction of stroke risk in adults with symptomatic intracranial atherosclerotic stenosis, defined as 50 to 99 percent narrowing. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Standardized medical therapy targeting vascular risk factors and stroke prevention
How many people
400 participants
Where
1 siteChina
Study dates
1 Dec 2025to 1 Jan 2028
How long will I take part?
12 Months
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults aged 18 to 80 years with symptomatic intracranial atherosclerotic stenosis (50%-99%) of a major anterior-circulation artery, who experienced a target-artery-related ischemic event (ischemic stroke involving <50% MCA territory or TIA) within the past 12 months and are eligible for medical therapy and DPR evaluation.

Who may be able to join

  • Patients with intracranial atherosclerotic stenosis (ICAS) of the anterior circulation.
  • History of an ischemic cerebrovascular event related to the target artery within the past 12 months, including ischemic stroke involving less than one-half of the middle cerebral artery territory or transient ischemic attack.
  • Age between 18 and 80 years.
  • Stenosis severity of 50% to 99% identified by transcranial Doppler ultrasound, CT angiography, or MR angiography, and confirmed as 50% to 99% stenosis on digital subtraction angiography.
  • Good compliance, willingness to sign written informed consent, and ability to complete follow-up.

Who cannot join

  • Non-atherosclerotic intracranial stenosis such as moyamoya disease, vasculitis, or arterial dissection.
  • Coexisting ipsilateral arterial stenosis greater than 50% other than the target lesion.
  • Large territorial infarction on MRI DWI involving at least one-half of the MCA territory with a modified Rankin Scale score greater than 3.
  • Contraindications to the use of antiplatelet agents or statins.
  • Inability to undergo DSA because of severe iodinated contrast allergy, severe hyperthyroidism, severe coagulation abnormalities with high bleeding risk, or severe cardiac, hepatic, or renal insufficiency.
  • Pregnant or breastfeeding women.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Department of Neurosurgery, Xuanwu hospital

    Beijing, Xicheng District, 100053

Other trials in China

About this study

Official title: Digital Angiography-Based Hemodynamic Assessment for Stroke Risk Stratification in Intracranial Arterial Stenosis

The goal of this observational study is to learn whether a digital angiography derived fractional flow reserve (DPR) measurement can improve the prediction of stroke risk in adults with symptomatic intracranial atherosclerotic stenosis, defined as 50 to 99 percent narrowing.

The main questions it aims to answer are:

Read more

Does DPR identify patients who are at higher risk of recurrent stroke despite receiving standard medical treatment? Is DPR more accurate than traditional angiographic stenosis measurements for assessing the functional severity of intracranial arterial disease?

Participants will undergo routine digital subtraction angiography as part of their clinical evaluation. Their angiographic images will be analyzed using a computational method to estimate blood flow impairment, and they will be followed for up to 12 months to monitor stroke related outcomes.

Read the detailed description

Intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke, representing ~15% of cases in Western populations and up to 46.6% in Asia. Even with intensive medical therapy, annual stroke recurrence remains high (7.2-20%), prompting exploration of additional treatment strategies. Early trials such as SAMMPRIS and VISSIT suggested worse outcomes with stenting compared with aggressive medical therapy, largely due to concerns over operator experience, patient selection, and timing. Subsequent analyses showed that patients with hemodynamic compromise-such as watershed infarction and poor collaterals-have recurrence rates up to 37%, underscoring the central role of impaired cerebral perfusion.

Although more recent studies (CASSISS, BASIS) demonstrated that endovascular therapy may be safe and effective in carefully selected patients, current ICAS assessment relies primarily on stenosis severity, which correlates only weakly with true hemodynamic impairment and is insufficient for accurate risk stratification. Because symptoms arise principally from reduced perfusion, physiologic evaluation is essential.

Fractional flow reserve (FFR) is the gold standard for assessing coronary lesion significance and guiding intervention through translesional pressure gradients. Attempts to translate this approach to ICAS using invasive pressure wires have shown feasibility but remain limited by anatomical differences, lack of dedicated devices, procedural risks, and unclear outcome thresholds.

Our prior work demonstrated that intracranial translesional pressure gradients correlate strongly with cerebral blood flow in both animal models and clinical settings, validating hemodynamic relevance. To overcome the limitations of invasive measurements, the present study seeks to develop and evaluate a noninvasive, angiography-derived pressure ratio (DPR) using routine digital subtraction angiography. This method allows physiologic assessment without pressure wires and may reduce procedural risk.

The objectives of this project are to establish a computational DPR technique, determine its association with clinical outcomes, identify a hemodynamic threshold for stroke-risk stratification, and validate its performance in a prospective multicenter cohort. By enabling early identification of high-risk ICAS patients who may respond poorly to medical therapy, DPR has the potential to improve treatment selection and outcomes, ultimately advancing strategies for stroke prevention.

Being tested
Standardized medical therapy targeting vascular risk factors and stroke prevention
Keywords
Intracranial Atherosclerotic Stenosis, Recurrent Stroke Risk, Hemodynamic Impairment, Fractional Flow Reserve, Precision Risk Stratification
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standardized medical therapy targeting vascular risk factors and stroke preventionDrug

    Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines

Study groups in NCT07309705
Study groupRoleWhat they receive
CASSISS-DPRNot described
Receives: Drug: Standardized medical therapy targeting vascular risk factors and stroke prevention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

    the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

    Measured: Baseline to 12 months (±2 months)

Secondary outcomes (5)
  1. transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year

    the number of participants who suffer from transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year after enrollment.

    Measured: Baseline to 12 months (±2 months)

  2. TIA related to ischemia in the qualifying artery territory within 1 year

    the number of participants who suffer from TIA related to ischemia in the qualifying artery territory within 1 year

    Measured: Baseline to 12 months (±2 months)

  3. any stroke/TIA/ death within 1 year

    the number of participants who suffer from any stroke/TIA/ death within 1 year

    Measured: Baseline to 12 months (±2 months)

  4. hemodynamic ischemic stroke in the qualifying artery territory within 1 year

    the number of participants who suffer from hemodynamic ischemic stroke in the qualifying artery territory within 1 year

    Measured: Baseline to 12 months (±2 months)

  5. embolic stroke within in the qualifying artery territory 1 year

    the number of participants who suffer from embolic stroke within in the qualifying artery territory 1 year

    Measured: Baseline to 12 months (±2 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Dec 2025
  2. Study start1 Dec 2025
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion1 Jan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07309705
Sponsor's protocol ID
CASSISS-DPR
Other IDs
WKZX2025CZ0401
Acronym
CASSISS-DPR
Status last verified
Dec 2025
First submitted
15 Dec 2025
Last updated
30 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in